Zifanocycline (TFA)

Zifanocycline (KBP-7072) TFA is an orally active, semi-synthetic aminomethylcycline antibiotic that inhibits the normal function of bacterial ribosomes. Zifanocycline TFA has broad spectrum in vitro antimicrobial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline TFA is indicated for the study of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections[1][2].

Product Specifications

Product Name Alternative

KBP-7072 (TFA)

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/zifanocycline-tfa.html

Purity

99.79

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O[C@]12[C@](C[C@@]3([H])C(C(C4=C(O)C(CN5CC6C(C6)C5)=CC(N(C)C)=C4C3)=O)=C2O)([H])[C@@H](C(O)=C(C1=O)C(N)=O)N(C)C.O=C(O)C(F)(F)F

Molecular Formula

C31H37F3N4O9

Molecular Weight

666.64

References & Citations

[1]Tan X, et al. Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models. Antimicrob Agents Chemother. 2020;64 (6) :e00488-20. Published 2020 May 21. [Content Brief]|[2]Lepak AJ, et al. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2019;63 (3) :e02404-18. Published 2019 Feb 26. [Content Brief]